DecisionPoint Financial’s Novavax NVAX Stock Holding History

DecisionPoint Financial’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$97	–	671
2025 Q1	$97	Hold	15	–	–	﹤0.01%	246
2024 Q4	$121	Buy	+15	New	+$145	﹤0.01%	254

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DecisionPoint Financial's NVAX Position: Q2 2025 in Review

DecisionPoint Financial sold out of Novavax (NVAX) in Q2 2025, closing a stake of 15 shares — an estimated $97 sold.

DecisionPoint Financial first reported a position in NVAX in Q4 2024 and held it in 2 quarters. The position peaked at $121 in Q4 2024. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

DecisionPoint Financial reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
DecisionPoint Financial sold 15 Novavax shares in Q2 2025, an estimated $97.
DecisionPoint Financial first reported a position in Novavax in Q4 2024 and held it in 2 quarters.
DecisionPoint Financial's Novavax position peaked at $121 in Q4 2024.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on DecisionPoint Financial's 13F filing for Q2 2025, filed 14 Aug 2025.